Slide 1: Full Year 2021 Results
Full Year 2021 Results Matthias Gaertner (CEO), Falk Neukirch (CFO) March 29, 2022
Slide 2: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 2
Slide 3: Highlights to date: Record FY 2021, sustainable growth story
Highlights to date: Record FY 2021, sustainable growth story Ongoing progress in strategy implementation • Two game-changing acquisitions: Cranach Pharma (PS) & NewCo Pharma (PST) • Continuous screening of M&A targets: focus on compounding, internationalization, new segment Pharmaceutical Supply (PS
Slide 4: Recent two game-changing acquisitions
Recent two game-changing acquisitions Acquisition of Cranach Pharma GmbH Acquisition of NewCo Pharma GmbH • Activities across Germany • Strong foothold in Western and South-Western Germany • Well established wholesale of specialty pharma drugs; GDP1-compliant • 5 compounding facilities with >200,000
Slide 5: Acquisition of NewCo Pharma - Transaction summary
Acquisition of NewCo Pharma - Transaction summary • 100% of NewCo Pharma Group Acquisition • Among the leading Patient-Specific Therapies providers; focus on Western and South-Western Germany Size & • ~ €118m purchase price Purchase price • Purchase price/EBITDA multiple: ~ 8 • Shares: ~ €32.7m1 - 9
Slide 6: Compounding Facilities
Leading Specialty Pharma provider with nationwide market coverage Medios NewCo Pharma • Around 50 specialized Tier 1 partner pharmacies added to Medios network Compounding Facilities Berlin • Portfolio of compounding preparations Blistering extended • Compounding volume and capacity expanded • Incre
Slide 7: Significant cross-selling potential in terms of products / clients
Significant cross-selling potential in terms of products / clients Oncology Ophthalmology Antibiotics Pain Management Hemophilia Neurology HIV Compounding materials Autoimmunology Parenteral Nutrition Infusions (oncology, others) Infusions (cytostatic, antibody, etc.) Patient-specific blistering Cli
Slide 8: Quarterly recovery after Q2 2020 Corona-related revenue & sales decline
Quarterly recovery after Q2 2020 Corona-related revenue & sales decline Revenue €m EBITDA pre¹ €m 369 354 10.2 10.0 9.5 316 319 8.8 163 160 174 4.3 4.8 130 3.8 2.8 2.5 2.2 margin 3.0 2.8 2.7 2.7 2.3 1.6 1.9 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2020 2021 2020 2021 ¹ EBITDA without extraord
Slide 9: Dynamic growth: driven by acquisition of Cranach Pharma
Dynamic growth: driven by acquisition of Cranach Pharma Revenue €m EBITDA pre¹ €m EBT pre¹ €m • Guidance 2021: • Revenue guidance exceeded • EBITDA pre within guidance range • EBT pre slightly above guidance range 1,357 38.4 32.3 627 15.1 12.0 FY 2020 FY 2021 FY 2020 FY 2021 FY 2020 FY 2021 ¹ EBITDA
Slide 10: Ambitious ESG strategy 2025
Ambitious ESG strategy 2025: 34 targets, realized through 65 measures using 57 different KPIs 12/21: Publication of Medios’ ESG strategy 2025: 2022 57 external and internal KPIs to track progress of • Implement IT-based ESG-platform activities; first data 2021 included in the Nonfinancial • Increase
Slide 11: Financial overview
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 11
Slide 12: FY 2021 – Financials
FY 2021 – Financials In € million FY 2021 FY 2020 ∆% Revenue 1,357.4 626,5 116.7 • Revenue more than doubled: mainly inorganic growth Gross profit (Revenue-Cost of materials) 70.1 38.1 84.2 • Lower gross margin due to weighting effect: gross margin in % 5.2% 6.1% over-proportional increase of PS3 EB
Slide 13: FY 2021 – Record year driven by strong inorganic and organic growth
FY 2021 – Record year driven by strong inorganic and organic growth FY YoY Revenue in €m FY 2020 Organic Inorganic FY 2021 Pharmaceutical Supply 564.3 95.3 635.0 1,294.5 • Organic growth 15% yoy thereof Cranach Pharma1 0.0 0.0 635.5 635.5 • Flat compounding revenue (PST) Patient-specific Therapies 6
Slide 14: Q4 2021 – Revenue-bridge per segment
Q4 2021 – Revenue-bridge per segment Q4 YoY Revenue in €m Q4 2020 Organic Inorganic Q4 2021 Pharmaceutical Supply 158.2 27.7 166.9 352.8 • Around 16% organic growth in Q4 thereof Cranach Pharma1 0 0 166.9 166.9 2021 supported by synergy effects Patient-specific Therapies 15.3 0.4 0 15.7 thereof Koel
Slide 15: FY 2021 – Substantial improvement of earnings margins
FY 2021 – Substantial improvement of earnings margins Pharmaceutical Patient-specific Internal Services and Group Supply Therapies IFRS consolidation In € million FY 2021 FY 2020 FY 2021 FY 2020 FYM 2021 FY 2020 FY 2021 FY 2020 Revenue (external) 1,295 564.3 62.2 61.9 0.7 0.4 1,357 626.5 delta (y-o-
Slide 16: Guidance 2022
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 16
Slide 17: Forecast FY 2022
Forecast FY 2022 In € million 2022F¹ 2021P3 Growth % Group revenue 1,450 – 1,600 1,357.4 6.8 – 17.9 + External growth will be substantially driven by the acquisition of NewCo Pharma + Synergy effects as a result of the integration of the acquisitions of Cranach Pharma & Newco Pharma: EBITDA pre² 52
Slide 18: Growth strategy - Clear plan for overall growth
Growth strategy - Clear plan for overall growth • Compounding capacities to triple as a result of • Compounding from partner pharmacies to be new labs in Berlin potentially integrated into Medios’ labs • Advance market penetration through innovative • Add further labs in case of geographical fit and
Slide 19: Appendix
1 Executive summary 2 Financial overview 3 Guidance 2022 4 Appendix 19
Slide 20: Key figures (1/2)
Key figures (1/2) in € thousand FY 2021 FY 2020 ∆ in % Q4 2021 Q4 2020 ∆ in % Revenue 1,357,408 626,543 116.7 368,643 173,644 112.3 Pharmaceutical Supply 1,294,531 564,252 129.4 352,786 158,208 123.0 Patient-Specific Therapies 62,230 61,883 0,6 15,685 15,339 2.3 Services 648 408 58.8 171 97 76.3 EBI
Slide 21: Key figures (2/2)
Key figures (2/2) in € thousand FY 2021 FY 2020 ∆ in % Q4 2021 Q4 2020 ∆ in % Earnings per share (in €) Undiluted 0.37 0.36 2.8 -0.13 0.08 -262.5 Diluted 0.37 0.35 5.7 -0.11 0.08 -237.5 Investments (CAPEX) 12,821 4,862 163.7 3,873 1,722 124.9 Cash flow from operating activities 61,520 -38,115 -261.4
Slide 22: Consolidated statement of comprehensive income
Consolidated statement of comprehensive income In € thousand FY 2021 FY 2020 Q4 2021 Q4 2020 Revenue 1,357,408 626,543 368,643 173,644 Change in stocks of finished goods and -19 -7 -19 -52 work-in-progress Work performed and capitalized 1,117 352 712 334 Other income 1,616 468 1,251 181 Cost of mate
Slide 23: Consolidated balance sheets FY 2021
Consolidated balance sheets FY 2021 Assets In € thousand Dec 31, 21 Dec 31,20 Liabilities In € thousand Dec 31, 21 Dec 31, 20 Non-current assets 223,473 58,232 Equity Intangible assets 192,861 35,237 Subscribed capital 22,881 16,085 Capital reserves 342,567 105,026 Property, plant and 13,713 5,337 A
Slide 24: Consolidated cash flow statement FY/Q4 2021 (1/2)
Consolidated cash flow statement FY/Q4 2021 (1/2) In € thousand FY 2021 FY 2020 Q4 2021 Q4 2020 Cash flow from operating activities Net income for the year 7,402 5,525 -2,488 1,255 Depreciation and amortization on non-current assets 19,374 3,551 7,778 983 Decrease/increase in provisions -937 11 -836
Slide 25: Consolidated cash flow statement FY/Q4 2021 (2/2)
Consolidated cash flow statement FY/Q4 2021 (2/2) In € thousand FY 2021 FY 2020 Q4 2021 Q4 2020 Cash flow from investment activities Payments made for investments in intangible assets -2,922 -2,142 -972 -847 Payments made for investments in property, plant and equipment -9,899 -2,720 -2,901 -783 Pay
Slide 26: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 c.nickolaus@medios.ag 26
Slide 27: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 28: Full Year 2021 Results
Full Year 2021 Results Matthias Gaertner (CEO), Falk Neukirch (CFO) March 29, 2022